Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02247531 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
NCT02247531 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 975 participants.
The verdict
NCT02247531, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
Study Summary
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Interventions
- OTHER Sham Comparator
- DRUG Lampalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2014-10-06 |
| Est. Completion | 2018-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02247531
The ClinicalTrials.gov registry entry for NCT02247531 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT02247531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02247531 about?
NCT02247531 is a clinical study titled "A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration". This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
What is the current status of trial NCT02247531?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2014-10-06. Estimated completion is 2018-01-23.
What interventions are being tested in trial NCT02247531?
The interventions under investigation include: Sham Comparator (OTHER), Lampalizumab (DRUG).
Who is sponsoring clinical trial NCT02247531?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.